Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2016 (2016), Article ID 7678901, 9 pages
http://dx.doi.org/10.1155/2016/7678901
Research Article

Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph

1School of Medicine, Department of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2Haematologic Technologies, Incorporated, Essex Junction, VT 05452, USA
3Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE 68588, USA
4Biosciences Division, Emergent BioSolutions Incorporated, Winnipeg, MB, Canada R3T 5Y3
5University of Manitoba, Winnipeg, MB, Canada R3T 2N2

Received 29 September 2015; Accepted 14 January 2016

Academic Editor: David Varon

Copyright © 2016 Dougald M. Monroe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Berntorp, S. Björkman, M. Carlsson, S. Lethagen, and I. M. Nilsson, “Biochemical and in vivo properties of high purity factor IX concentrates,” Thrombosis and Haemostasis, vol. 70, no. 5, pp. 768–773, 1993. View at Google Scholar · View at Scopus
  2. K. Hansson and J. Stenflo, “Post-translational modifications in proteins involved in blood coagulation,” Journal of Thrombosis and Haemostasis, vol. 3, no. 12, pp. 2633–2648, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. A. Limemani, K. P. Gowell, and S. R. Deitcher, “High-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential,” Acta Haematologica, vol. 94, supplement 1, pp. 12–17, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Bond, M. Jankowski, H. Patel et al., “Biochemical characterization of recombinant factor IX,” Seminars in Hematology, vol. 35, no. 2, pp. 11–17, 1998. View at Google Scholar · View at Scopus
  5. B. Furie and B. C. Furie, “The molecular basis of blood coagulation,” Cell, vol. 53, no. 4, pp. 505–518, 1988. View at Publisher · View at Google Scholar · View at Scopus
  6. M.-H. Lee, Y.-S. Lin, C.-F. Tu, and C.-H. Yen, “Recombinant human factor IX produced from transgenic porcine milk,” BioMed Research International, vol. 2014, Article ID 315375, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Nishimura, S. Kawabata, W. Kisiel et al., “Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl2-Glc) O-glycosidically linked to a serine residue in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z,” The Journal of Biological Chemistry, vol. 264, no. 34, pp. 20320–20325, 1989. View at Google Scholar · View at Scopus
  8. R. J. Harris, H. van Halbeek, J. Glushka et al., “Identification and structural analysis of the tetrasaccharide NeuAcα(26)Galβ(14)GlcNAcβ(13)Fucα1O-linked to serine 61 of human factor IX,” Biochemistry, vol. 32, no. 26, pp. 6539–6547, 1993. View at Publisher · View at Google Scholar
  9. G.-C. Gil, W. H. Velander, and K. E. Van Cott, “Analysis of the N-glycans of recombinant human factor IX purified from transgenic pig milk,” Glycobiology, vol. 18, no. 7, pp. 526–539, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Makino, K. Omichi, N. Kuraya et al., “Structural analysis of N-linked sugar chains of human blood clotting factor IX,” Journal of Biochemistry, vol. 128, no. 2, pp. 175–180, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. T. R. Baird and P. N. Walsh, “The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation,” The Journal of Biological Chemistry, vol. 277, no. 41, pp. 38462–38467, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. D. M. Monroe, M. Hoffman, and H. R. Roberts, “Platelets and thrombin generation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 9, pp. 1381–1389, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. M. J. Griffith, H. M. Reisner, R. L. Lundblad, and H. R. Roberts, “Measurement of human factor IXa activity in an isolated factor X activation system,” Thrombosis Research, vol. 27, no. 3, pp. 289–301, 1982. View at Publisher · View at Google Scholar · View at Scopus
  14. P. M. Aggeler, S. G. White, M. B. Glendening, E. W. Page, T. B. Leake, and G. Bates, “Plasma thromboplastin component (PTC) deficiency; a new disease resembling hemophilia,” Proceedings of the Society for Experimental Biology and Medicine, vol. 79, no. 4, pp. 692–694, 1952. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Ljung, A. Wallmark, and I. M. Nilsson, “Two allotypes of factor IX present in haemophilia B,” Scandinavian Journal of Haematology, vol. 37, no. 5, pp. 411–416, 1986. View at Google Scholar · View at Scopus
  16. A. Wallmark, G. Kunkel, H. Mouhli et al., “Population genetics of the Malmö polymorphism of coagulation factor IX,” Human Heredity, vol. 41, no. 6, pp. 391–396, 1991. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Gillis, B. C. Furie, B. Furie et al., “γ-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function,” Protein Science, vol. 6, no. 1, pp. 185–196, 1997. View at Google Scholar · View at Scopus
  18. T. Chase Jr. and E. Shaw, “Comparison of the esterase activities of trypsin, plasmin, and thrombin on guanidinobenzoate esters. Titration of the enzymes,” Biochemistry, vol. 8, no. 5, pp. 2212–2224, 1969. View at Publisher · View at Google Scholar · View at Scopus
  19. K. R. Anumula, “Rapid quantitative determination of sialic acids in glycoproteins by high-performance liquid chromatography with a sensitive fluorescence detection,” Analytical Biochemistry, vol. 230, no. 1, pp. 24–30, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. K. R. Anumula and S. T. Dhume, “High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid,” Glycobiology, vol. 8, no. 7, pp. 685–694, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. J. C. Rouse, J. E. McClelland, H. K. Patel, M. A. Jankowski, and T. J. Porter, “Top-down characterization of protein pharmaceuticals by liquid chromatography/mass spectrometry: application to recombinant factor IX comparability-a case study,” Methods in Molecular Biology, vol. 308, pp. 435–460, 2005. View at Google Scholar
  22. R. Müller, M. Marchetti, M. Kratzmeier et al., “Comparison of planar SDS-PAGE, CGE-on-a-chip, and MALDI-TOF mass spectrometry for analysis of the enzymatic de-N-glycosylation of antithrombin III and coagulation factor IX with PNGase F,” Analytical and Bioanalytical Chemistry, vol. 389, no. 6, pp. 1859–1868, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. L. V. Medved, A. Vysotchin, and K. C. Ingham, “Ca2+-dependent interactions between Gla and EGF domains in human coagulation factor IX,” Biochemistry, vol. 33, no. 2, pp. 478–485, 1994. View at Publisher · View at Google Scholar
  24. H. Li, S. Bai, J. Y. Wei, S. A. Berkowitz, and M. L. Brader, “Calcium binding to a factor IX Fc fusion protein and effects on higher-order structure,” Journal of Pharmaceutical Sciences, vol. 100, no. 11, pp. 4597–4606, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Kurachi, S. Kurachi, M. Furukawa, and S.-N. Yao, “Biology of factor IX,” Blood Coagulation and Fibrinolysis, vol. 4, no. 6, pp. 953–974, 1993. View at Publisher · View at Google Scholar · View at Scopus
  26. S. A. Limentani, K. P. Gowell, and S. R. Deitcher, “In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B,” Thrombosis and Haemostasis, vol. 73, no. 4, pp. 584–591, 1995. View at Google Scholar · View at Scopus
  27. Inspiration Biopharmaceuticals, “Inspiration Biopharmaceuticals announces clinical hold of clinical trials evaluating IB1001 for the treatment and prevention of bleeding in hemophilia B,” 2012, http://hemophiliafed.org/uploads/2012/07/IBI-press-release.pdf.
  28. B. Drobic, Y. Hua, T. Babinchak, E. Gomperts, and C. Hall, “Evaluation of host cell protein immunogenicity of a polished recombinant factor IX investigational product, IB1001 in previously treated patients with hemophilia B,” Journal of Thrombosis and Haemostasis, vol. 13, S2, p. 323, 2015, Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis, June 20–25, 2015. View at Google Scholar
  29. E. Gray, J. Tubbs, S. Thomas et al., “Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity,” Thrombosis and Haemostasis, vol. 73, no. 4, pp. 675–679, 1995. View at Google Scholar · View at Scopus
  30. Y. Yu and C. M. Millar, “Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays,” Journal of Thrombosis and Haemostasis, vol. 12, no. 1, pp. 62–70, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. J. A. Samis, G. D. Ramsey, J. B. Walker, M. E. Nesheim, and A. R. Giles, “Proteolytic processing of human coagulation factor IX by plasmin,” Blood, vol. 95, no. 3, pp. 943–951, 2000. View at Google Scholar · View at Scopus
  32. C. Prowse and D. S. Pepper, “In vitro tests of the potential thrombogenicity of factor IX concentrates: inhibition and characterisation studies of NAPTT, TGt50 and PF3 moieties,” Thrombosis Research, vol. 20, no. 5-6, pp. 491–498, 1980. View at Publisher · View at Google Scholar · View at Scopus
  33. C. V. Prowse and A. E. Williams, “A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models,” Thrombosis and Haemostasis, vol. 44, no. 2, pp. 81–86, 1980. View at Google Scholar · View at Scopus
  34. J. Stenflo, P. Fernlund, W. Egan, and P. Roepstorff, “Vitamin K dependent modifications of glutamic acid residues in prothrombin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 71, no. 7, pp. 2730–2733, 1974. View at Publisher · View at Google Scholar · View at Scopus
  35. G. L. Nelsestuen, M. Broderius, T. H. Zytkovicz, and J. B. Howard, “On the role of γ-carboxyglutamic acid in calcium and phospholipid binding,” Biochemical and Biophysical Research Communications, vol. 65, no. 1, pp. 233–240, 1975. View at Publisher · View at Google Scholar · View at Scopus
  36. D. M. McCord, D. M. Monroe, K. J. Smith, and H. R. Roberts, “Characterization of the functional defect in factor IX Alabama: Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain,” The Journal of Biological Chemistry, vol. 265, no. 18, pp. 10250–10254, 1990. View at Google Scholar · View at Scopus
  37. G. Chevreux, V. Faid, M.-H. Andre, Z. Tellier, and N. Bihoreau, “Differential investigations from plasma-derived and recombinant factor IX revealed major differences in post-translational modifications of activation peptides,” Vox Sanguinis, vol. 104, no. 2, pp. 171–174, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. P. M. Rallapalli, G. Kemball-Cook, E. G. Tuddenham, K. Gomez, and S. J. Perkins, “An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B,” Journal of Thrombosis and Haemostasis, vol. 11, no. 7, pp. 1329–1340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. B. M. Ewenstein, J. H. Joist, A. D. Shapiro et al., “Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B,” Transfusion, vol. 42, no. 2, pp. 190–197, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Lissitchkov, M. Matysiak, K. Zavilska et al., “Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B,” Haemophilia, vol. 19, no. 5, pp. 674–678, 2013. View at Publisher · View at Google Scholar
  41. U. Martinowitz, A. Shapiro, D. V. Quon et al., “Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis,” Haemophilia, vol. 18, no. 6, pp. 881–887, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. C.-T. Yuen, P. L. Storring, R. J. Tiplady et al., “Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures,” British Journal of Haematology, vol. 121, no. 3, pp. 511–526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. R. J. Solá and K. Griebenow, “Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy,” BioDrugs, vol. 24, no. 1, pp. 9–21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. J.-Y. Chang, J. Brock, M. J. Griffith, and D. M. Monroe, “Glycosylation of the activation peptide of factor IX determines plasma half-life,” Journal of Thrombosis and Haemostasis, vol. 5, supplement 2, p. 088, 2007. View at Publisher · View at Google Scholar